Israel Englander Enlivex Therapeutics Ltd. Call Options Transaction History
Millennium Management LLC
- $192 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ENLV
# of Institutions
25Shares Held
2.57MCall Options Held
79.1KPut Options Held
0-
Armistice Capital, LLC New York, NY1.41MShares$2.22 Million0.03% of portfolio
-
Morgan Stanley New York, NY219KShares$344,0630.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny168KShares$264,3750.0% of portfolio
-
Jane Street Group, LLC New York, NY61.1KShares$95,8510.0% of portfolio
-
Sigma Investment Counselors Inc28KShares$43,9600.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $28.9M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...